E. Anders Kolb, M.D.
E. Anders Kolb, M.D., a world-renowned pediatric hematologist oncologist and researcher, is president and chief executive officer of The Leukemia & Lymphoma Society (LLS), a global leader in the fight against cancer. Dr. Kolb leads the mission and operations of this $500 million cancer patient advocacy agency with offices serving patients and families across North America.
Dr. Kolb has devoted his life's work to caring for children with pediatric blood cancer and conducting research to find cures. Before joining LLS, he spent 15 years at Nemours Children's Health, where he built the Blood and Bone Marrow Transplant Program and most recently served as chief of the Division of Hematology and Oncology, Director of the Moseley Foundation Institute for Cancer and Blood Disorders, and Vice Chairman for Research in the Department of Pediatrics at the Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb will remain as part-time faculty at Nemours with some limited patient care responsibilities.
Prior to his roles at Nemours, Dr. Kolb was a member of the Pediatric Leukemia and Pediatric Stem Cell Transplantation Services at Memorial Sloan-Kettering Cancer Center in New York City; Director of the Pediatric Preclinical Chemotherapy Testing Laboratory at the Albert Einstein Cancer Center, Albert Einstein College of Medicine in the Bronx; and Director of the Pediatric Leukemia and Lymphoma Service and Pediatric Stem Cell Transplantation at The Children's Hospital at Montefiore, also in the Bronx.
Dr. Kolb has been the principal or co-principal investigator of numerous studies and grants, including clinical trials with the Children's Oncology Group, the Nemours NCI Community Oncology Research Program (NCORP) and the Center of Biomedical Research Excellence (COBRE), which awarded Nemours Children's Health a $10.5 million grant to establish the Delaware Comprehensive Sickle Cell Research Center. From 2013 to 2023, he served as the Chair of the Children's Oncology Group Myeloid Disease Committee. From 2018 to 2023 he was co-chair and member of the executive committee of LLS PedAL.
Dr. Kolb has authored or co-authored more than 150 articles in peer-reviewed journals and received numerous awards.
Dr. Kolb completed his pediatric residency at St. Christopher's Hospital for Children and completed fellowship training in hematology/oncology in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center. He earned his M.D. from Thomas Jefferson University and his bachelor's degree from the University of Pennsylvania.
As chief financial officer, JR ensures that LLS achieves the ambitious financial goals of its long-range strategic plan. Miller leads the finance organization and risk management and is responsible for enhancing LLS's financial efficiency and effectiveness in partnership with the organization's executive team.
Throughout his 20-year tenure at LLS, Miller served as a regional vice president, overseeing ten chapters across the U.S., and as vice president of field operations, in which he was responsible for management of LLS Canada. From 2015 to 2018, Miller served as CEO of PearlPoint, an online service that provides nutritional support for cancer patients, which he has since integrated into LLS’s family of patient support services.
Prior to joining LLS, Miller was in corporate accounting with David C. Cook, a nonprofit publishing company, and an internal auditor for Farm Family Insurance Companies.
Miller holds a bachelor’s degree in accounting from Gordon College and is a member of the American Institute of Certified Public Accountants.
Gwen Nichols, M.D.
As The Leukemia & Lymphoma Society's (LLS) Chief Medical Officer (CMO), Gwen Nichols, M.D., plays a critical role in advancing cures through a unique combination of clinical, academic and pharmaceutical experience. She oversees LLS's scientific research portfolio, patient services and policy and advocacy initiatives. Dr. Nichols leads an international team of preeminent leaders in pediatric acute leukemia to conceive, develop and implement LLS PedAL, a first of its kind global master clinical trial and a key component of the Dare to Dream Project, transforming treatment and care for kids with blood cancer.
A physician and scientific researcher, Dr. Nichols has dedicated her career to advancing cures for cancers. Before joining LLS, she was oncology site head of the Roche Translational Clinical Research Center, where she worked to develop new cancer therapies, translating them from the laboratory to clinical trials. Prior to joining Roche in 2007, Dr. Nichols was at Columbia University for more than ten years, where she served as the director of the Hematologic Malignancies Program.
While at Columbia University, Dr. Nichols maintained an active clinical practice and received the prestigious honors of "Physician of the Year" from Columbia University and the "Humanism in Medicine Award" from the American Association of Medical Colleges.
As General Counsel and Chief People Officer, Dale Nissenbaum is responsible for leading both the Legal and Compliance functions and LLS' Human Resources team. She is the liaison to the LLS Board of Directors for the executive leadership team, and advises the Board on developing and maintaining best practices in corporate governance policies.
Dale has over 25 years of legal experience, developed at both public and private companies. Before joining LLS, she was the General Counsel, Americas, for Brunswick Group, a global critical communications firm, from 2012 to 2019. Before that she was the General Counsel and Chief Human Resources Officer at a privately held manufacturing company. While in private practice, she was a mergers and acquisitions attorney at Weil.
She has a bachelor's degree in history and political science from the University of Pennsylvania and a Juris Doctor degree from Columbia University School of Law.